Context: The species-specific differences and mechanisms of action of bee pollen on reproduction have not been well studied.
Objective: We compared the effects of bee pollen extracts from different plants on ovarian cell functions.
Materials And Methods: We compared the effects of pollens from black alder, dandelion, maize, rapeseed, and willow at 0, 0.01, 0.1, 1, 10, or 100 µg/mL on cultured porcine ovarian granulosa cells. Cell viability was assessed with a Trypan blue test, the cell proliferation marker (PCNA), and an apoptosis marker (BAX) were assessed by immunocytochemistry. Insulin-like growth factor (IGF-I) release was measured by an enzyme-linked immunosorbent assay.
Results: Addition of any bee pollen reduced cell viability, promoted accumulation of both proliferation and apoptosis markers, and promoted IGF-I release. The ability of various pollens to suppress cell viability ranked as follows: rapeseed > dandelion > alder > maize > willow. The biological activity of bee pollens regarding their stimulatory action on ovarian cell proliferation ranked as follows: dandelion > willow > maize > alder > rapeseed. Cell apoptosis was promoted by pollens as follows: range > dandelion > alder > rapeseed > willow > maize. The ability of the pollens to stimulate IGF-I output are as follows: willow > dandelion > rapeseed > maize > alder.
Discussion: Bee pollen can promote ovarian cell proliferation by promoting IGF-I release, but it induces the dominance of apoptosis over proliferation and the reduction in ovarian cell viability in a species-specific manner.
Conclusions: This is the first demonstration of adverse effects of bee pollen on ovarian cell viability and of its direct stimulatory influence on proliferation, apoptosis, and IGF-I release. The biological potency of bee pollen is dependent on the plant species.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646543 | PMC |
http://dx.doi.org/10.1080/13880209.2020.1839514 | DOI Listing |
Hum Reprod Update
January 2025
Amsterdam UMC, Location Vrije Universiteit Amsterdam, Centre of Expertise on Gender Dysphoria, Amsterdam, The Netherlands.
Background: Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from their birth gender. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth or become a biological parent.
Objective And Rationale: TGD people increasingly pursue help for their reproductive questions, including fertility, fertility preservation, active desire for children, and future options.
J Clin Pharmacol
January 2025
Eisai Inc., Nutley, NJ, USA.
The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum-resistant ovarian and non-small cell lung cancer. A pharmacometric assessment evaluated farletuzumab ecteribulin pharmacokinetics and exposure-response (E-R) relationships for efficacy and safety to support dose optimization. Patients received 0.
View Article and Find Full Text PDFJ Assist Reprod Genet
January 2025
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, Shandong, China.
Purpose: To investigate BMAL1 and BMP6 expressive differences in ovarian granulosa cells (OGCs) of patients with polycystic ovary syndrome (PCOS), explore regulatory relationship, assess their impacts on OGC proliferation and apoptosis, and analyze their correlations with ART outcomes of patients.
Methods: A clinical study selected 40 PCOS patients who underwent IVF/ICSI in our hospital from January to October 2022 and 39 controls with male or tubal factor infertility. RT-qPCR and Western blot assessed BMAL1 and BMP6 mRNA/protein levels.
J Mol Med (Berl)
January 2025
Division of Human Reproduction and Developmental Genetics, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, Zhejiang, China.
Primary ovarian insufficiency (POI) is a disease defined as a reduction in ovarian function under the age of 40 and represents the main cause of female infertility. In recent years, many genetic mutations associated with POI have been identified using high-throughput sequencing technology. However, one big challenge today is to determine the disease-causing gene associations through functional assessment.
View Article and Find Full Text PDFJ Gynecol Oncol
January 2025
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Objective: To evaluate the efficacy of immune checkpoint inhibitors (ICIs) for fertility-sparing treatment in Lynch syndrome-associated endometrial cancer (LS-EC).
Methods: Four LS-EC cases received programmed cell death protein 1 (PD-1) inhibitors for fertility preservation at the Obstetrics and Gynecology Hospital of Fudan University from 2017 to 2023. The clinical data and long-term outcomes were retrospectively reviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!